This Article  • References  • Full text PDF  • Reply to article  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citation map  • Contact me when this article is cited  Related Content  • Similar articles in this journal  Social Bookmarking   What's this?

Ronald F. Pfeiffer, MD; Kathleen Wilken, MD; Carolyn Glaeske, RN; Agapito S. Lorenzo, MD

Arch Neurol. 1985;42(6):586-588.

Abstract
• The efficacy of low-dose bromocriptine mesylate administration (20 mg daily or less) was evaluated in a double-blind study. Nine of 16 individuals receiving bromocriptine completed the 40-week study. Modest, but significant, improvement was derived from bromocriptine therapy. Improvement was most evident in tremor. Maximum improvement was achieved with doses between 7.5 and 15.0 mg daily, with some decline in efficacy as doses approached 20 mg. Adverse effects were common, but were generally mild in severity. Our results suggest that bromocriptine in low doses may be an effective adjunct to carbidopa and levodopa (Sinemet) in the treatment of Parkinson's disease.

Author Affiliations
From the Departments of Neurology (Drs Pfeiffer, Wilken, and Lorenzo and Ms Glaeske) and Pharmacology (Dr Pfeiffer), University of Nebraska Medical Center, Omaha.

Footnotes
Accepted for publication May 10, 1984.

Reprint requests to University of Nebraska Medical Center, 42nd and Dewey Avenue, Room 4102, Omaha, NE 68105 (Dr Pfeiffer).

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter     What's this?